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Introduction: In a recent global phase 3 trial, patients with ad-
vanced non-small cell lung cancer (NSCLC), who had not pro-
gressed after four cycles of platinum-based induction chemotherapy,
were randomized to maintenance therapy with pemetrexed or pla-
cebo. The objective of this retrospective, exploratory, post hoc
subgroup analysis was to compare outcomes of East Asian patients
with non-East Asian patients treated with pemetrexed or placebo.
Methods: Only patients with nonsquamous histology were ana-
lyzed. Patients were grouped by enrollment location (East Asian 
China, Korea, or Taiwan; non-East Asian all other countries). The
Kaplan–Meier method was used to calculate median progression-
free survival (PFS) and overall survival (OS) times. Hazard ratios
(HRs) were calculated using unadjusted Cox proportional hazard
models.
Results: Of the 663 patients enrolled in the study, 481 patients had
nonsquamous NSCLC: East Asian  27% and non-East Asian 
73%. In the East Asian subgroup, there were more women, never
smokers, and patients with adenocarcinoma. PFS was similar be-
tween the subgroups and significantly prolonged in patients treated
with pemetrexed than placebo (median PFS: East Asian, 4.4 versus
1.6 months, HR  0.42, p  0.001; non-East Asian, 4.5 versus 2.8
months, HR  0.45, p  0.001). OS was numerically prolonged in
East Asians (median OS: pemetrexed, 19.7 months; placebo, 16.4
months) compared with non-East Asians (pemetrexed, 13.2 months;
placebo, 8.5 months). Pemetrexed was reasonably well tolerated
with few severe adverse events reported.
Conclusion: The results of this subgroup analysis support pem-
etrexed as maintenance therapy for East Asian patients with ad-
vanced, nonsquamous NSCLC.
Key Words: Carcinoma, Non-small cell lung, East Asian, Mainte-
nance therapy, Nonsquamous, Pemetrexed.
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Pemetrexed is a multitargeted, antifolate, cytotoxic drugthat is currently approved for the treatment of advanced
non-small cell lung cancer (NSCLC) in patients with nons-
quamous histology.1,2 Pemetrexed is approved in combina-
tion with cisplatin for first-line therapy, as a single agent for
second-line therapy, and as a single agent for maintenance
therapy.1 In a recent global phase 3 trial (H3E-MC-JMEN
[JMEN]), patients with advanced NSCLC, who had not
progressed after four cycles of platinum-based induction
chemotherapy, were randomized to maintenance therapy with
pemetrexed or placebo until disease progression.3 In this trial,
progression-free survival (PFS) and overall survival (OS)
were significantly longer for patients treated with pemetrexed
(and best supportive care) than placebo (and best supportive
care). Furthermore, and consistent with current findings on
the efficacy of pemetrexed,2 a prespecified subgroup analysis
of the patients with nonsquamous histology showed a signif-
*Penn State Hershey Cancer Institute, Hershey, Pennsylvania; †Guangdong
Lung Cancer Institute, Guangdong General Hospital and Guangdong
Academy of Medical Sciences, Guangzhou, People’s Republic of China;
‡Taipei Veterans General Hospital, School of Medicine, National Yang-
Ming University, Taipei City, Taiwan, Republic of China; §Yonsei
Cancer Center, Yonsei University College of Medicine, Seoul, Republic
of Korea; Korea Cancer Center Hospital, Seoul, Republic of Korea;
¶Cancer Center of Sun Yat-Sen University, Guangzhou, People’s Re-
public of China; #Eli Lilly and Company, Indianapolis, Indiana; and
**Eli Lilly Interame´rica Inc., Buenos Aires, Argentina.
Disclosure: The institution of J.-H. Kim was reimbursed by Eli Lilly and
Company for a clinical trial related to the topic of the manuscript. C.P.
Belani has received honoraria from Eli Lilly and Company for consul-
tation and participation in advisory boards. Y.-L. Wu has received
honoraria from Eli Lilly and company for participating in an educational
program. P. Peterson is a full-time employee of Eli Lilly and company.
M. Orlando is a full-time employee and shareholder of Eli Lilly and
company. Y.-M. Chen, S.-H. Yang, and L. Zhang have no relevant
financial interests to declare.
Address for correspondence: Mauro Orlando, Medical Department, Eli Lilly
Interame´rica Inc., Edificio Panamericana Plaza, Tronador 4890 Piso 12,
Buenos Aires C1430DNN, Argentina. E-mail: orlando_mauro@lilly.com
Copyright © 2012 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/12/0703-0567
Journal of Thoracic Oncology • Volume 7, Number 3, March 2012 567
icant improvement in survival after pemetrexed treatment
(median PFS pemetrexed versus placebo  4.5 versus 2.6
months, hazard ratio [HR]  0.44; median OS pemetrexed
versus placebo  15.5 versus 10.3 months, HR  0.70). An
additional prespecified subgroup analysis, including all the
randomized patients, showed that East Asian patients had a
better prognosis for survival in both treatment arms compared
with patients enrolled from non-East Asian countries (HR 
0.56; 95% confidence interval [CI]: 0.41–0.76; p 0.0002).4
A similar result was also found in another global phase 3 trial
(H3E-MC-JMDB) in which patients with advanced NSCLC
were given first-line treatment with pemetrexed and cisplatin
or gemcitabine and cisplatin.5,6 Therefore, we conducted a
retrospective, exploratory, post hoc subgroup analysis of the
JMEN phase 3 trial3 to compare the efficacy and safety
outcomes of East Asian patients with non-East Asian patients
treated with maintenance pemetrexed or placebo.
PATIENTS AND METHODS
Study Design
Details of the multicenter, randomized, double-blind,
placebo-controlled study have been previously reported.3 The
study was conducted in accordance with the Declaration of
Helsinki and Good Clinical Practice guidelines and approved
by the participating institutional ethics review boards. All
patients were required to provide written, informed consent
before participating in the study. The clinical trial was reg-
istered at www.clinicaltrials.gov (NCT00102804). The first
patient was enrolled on March 4, 2005; the primary analysis
database lock was on November 21, 2007; and the final
database lock was on December 18, 2008.
Study Population
For the study, the inclusion criteria included the fol-
lowing: age 18 years, estimated life expectancy of at least
12 weeks, an Eastern Cooperative Oncology Group perfor-
mance status of 0 or 1, histological or cytological diagnosis of
stage IIIB or stage IV NSCLC before induction therapy, and
no progression during four cycles of platinum-based chemo-
therapy. For this analysis, the inclusion criteria also included
nonsquamous histology (this included patients with adeno-
carcinoma, large-cell carcinoma, and other or unknown his-
tology, i.e, all patients without a diagnosis of predominantly
squamous cell carcinoma). East Asian patients were defined
as those enrolled in China, Korea, or Taiwan. Non-East Asian
patients were defined as those enrolled in all other countries
(Australia, Austria, Brazil, Bulgaria, Croatia, Czech Repub-
lic, Germany, Greece, Hungary, India, Italy, the Netherlands,
Poland, Romania, Spain, Turkey, and the United States). Key
exclusion criteria for the study included a previous malig-
nancy other than NSCLC; inability to take corticosteroid
drugs, folic acid, or vitamin B12; uncontrolled cardiac dis-
ease; progressive brain metastases; or uncontrolled third-
space fluid collections.
Treatment Protocol
In brief, patients who had not progressed on four cycles
of platinum-based chemotherapy (gemcitabine–carboplatin,
gemcitabine–cisplatin, paclitaxel–carboplatin, paclitaxel–cis-
platin, docetaxel–carboplatin, or docetaxel–cisplatin) were
randomized in a 2:1 ratio to receive either pemetrexed (500
mg/m2; Alimta, Eli Lilly, Indianapolis, IN) or placebo (0.9%
sodium chloride) in 21-day cycles. All patients received best
supportive care, vitamin B12 and folic acid supplementation,
and dexamethasone prophylaxis throughout the study. Sam-
ple size, randomization, and masking details are provided in
the study by Ciuleanu et al.3 Using a minimization algorithm,
patients were randomly assigned according to disease stage,
Eastern Cooperative Oncology Group performance status,
sex, best response to induction therapy, nonplatinum compo-
nent on induction therapy, and history of brain metastases.
Patients continued treatment until disease progression or
discontinuation. Patients were discontinued from the study
treatment before they were administered second-line antican-
cer therapy.
Outcome Measures
The primary objective of the study was investigator-
assessed PFS. PFS was measured from the date of random-
ization to the first date of objective disease progression or
death. Tumors were measured by imaging (computed axial
tomography scans or magnetic resonance imaging). Baseline
tumor measurements were taken within 4 weeks of study
entry. Tumor response was assessed by the investigator every
two cycles using the Response Evaluation Criteria in Solid
Tumors.6 Tumor response was also independently assessed
for all patients who had a baseline scan and at least one
follow-up scan.
The secondary objectives of the study included OS and
safety. OS was measured from the date of randomization to
death. Adverse events were recorded before each cycle using
the Common Terminology for Criteria for Adverse Events
version 3.0.7 Adverse events that were considered, in the
opinion of the investigator, to be possibly related to the study
treatment were reported as drug-related adverse events. Post-
discontinuation (i.e., after study treatment discontinuation but
during the study observation period) second-line therapy for
NSCLC was recorded.
Statistical Analysis
The study was designed to test for superiority of pem-
etrexed over placebo for PFS and OS.3 PFS was the primary
outcome; statistical [alpha] error was controlled for both PFS
and OS. In the current analysis, based on expectations of
substantially superior survival among patients enrolled in
East Asian countries, efficacy and safety outcomes were
analyzed separately for randomized patients of East Asian
geography (those enrolled in China, Korea, and Taiwan) and
those of non-East Asian geography (those enrolled in other
parts of the world). The Kaplan–Meier method was used to
estimate PFS and OS parameters by treatment arm. Between-
treatment HRs were calculated using unadjusted Cox propor-
tional hazard models, with assigned treatment as the only
covariate. Descriptive statistics were reported for baseline
characteristics and safety data. All analyses were conducted
using SAS versions 8.0.2 and 9.1.3 (SAS, Cary, NC).
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RESULTS
Patient Disposition
Of the 663 patients enrolled in the study, 481 patients
had nonsquamous NSCLC (Figure 1). Of these patients, 129
of 481 (27%) were enrolled in East Asian countries and 352
of 481 (73%) were enrolled in non-East Asian countries
(Figure 1). Similar to the entire JMEN study population,
patients in both subgroups were allocated to pemetrexed or
placebo in a 2:1 ratio.
Patient Characteristics
There were differences in baseline patient characteris-
tics between the East Asian and the non-East Asian sub-
FIGURE 1. Patient flow diagram.
TABLE 1. Patient Characteristics
Characteristic
East Asian Non-East Asian
Pemetrexed
(n  88)
Placebo
(n  41)
Pemetrexed
(n  237)
Placebo
(n  115)
Median age, yr 58 62 61 60
Sex, n (%)
Men 44 (50) 25 (61) 179 (76) 83 (72)
Women 44 (50) 16 (39) 58 (24) 32 (28)
Smoking history, n (%)
Smoker (current or former) 42 (48) 16 (39) 182 (77) 91 (79)
Never smoker 46 (52) 25 (61) 52 (22) 23 (20)
Disease stage, n (%)
IIIB 17 (19) 11 (27) 38 (16) 19 (16)
IV 71 (81) 30 (73) 198 (84) 96 (84)
ECOG score, n (%)
0 29 (33) 16 (39) 104 (44) 44 (38)
1 59 (67) 25 (61) 131 (55) 71 (62)
Histology, n (%)
Adenocarcinoma 77 (88) 38 (93) 145 (61) 68 (59)
Large cell lung cancer 1 (1) 0 9 (4) 10 (9)
Other or unknown 10 (11) 3 (7) 83 (35) 37 (32)
Response to induction therapy, n (%)
Complete response 0 0 5 (2) 0
Partial response 33 (38) 19 (46) 110 (46) 59 (51)
Stable disease 54 (61) 22 (54) 120 (51) 56 (49)
Progressive disease 1 (1) 0 1 (1) 0
ECOG, Eastern Cooperative Oncology Group.
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groups (Table 1). In the East Asian group, there were more
women, more never smokers, and more patients with disease
histology of adenocarcinoma than in the non-East Asian
group. However, there were few differences in patient char-
acteristics between treatment arms within each group (Table
1). About half of the patients had a complete or partial
response to induction therapy.
Treatment Delivery
The number of maintenance cycles delivered and the
mean dose intensity were similar between the pemetrexed
treatment arms of both subgroups. Patients treated with pem-
etrexed in both the East Asian and the non-East Asian groups
received a median of six cycles of pemetrexed, and the mean
dose intensity was similar between the subgroups (East Asian
group, 161 mg/m2/wk; non-East Asian group, 158 mg/m2/
wk). Pemetrexed dose reductions were required by more
patients in the non-East Asian group than in the East Asian
group (8% versus 1%, respectively). Slightly more number of
patients completed at least six cycles of pemetrexed in the
East Asian group than in the non-East Asian group (60%
versus 52%), whereas a similar proportion of patients in both
groups completed at least 10 pemetrexed cycles (27% versus
25%). In the placebo treatment arm, the median number of
cycles of study therapy delivered was two in the East Asian
group and three in the non-East Asian group. Placebo dose
reductions were required by 2% of the patients in the East
Asian group and 1% of the patients in the non-East Asian
group. Similar proportions of patients in the East Asian and
non-East Asian subgroups completed at least 6 (22% versus
26%) or 10 cycles (5% versus 8%) of placebo treatment.
Efficacy
PFS was similar between the East Asian and non-East
Asian groups (Table 2 and Figure 2). For both the subgroups,
PFS was significantly prolonged in the pemetrexed arm than
in the placebo treatment arm. There was no difference in PFS
when assessed by the investigator or independently. In con-
trast, OS was numerically longer in the East Asian group than
in the non-East Asian group (Table 2 and Figure 3). For the
non-East Asian group, OS was significantly longer for the
pemetrexed arm than the placebo treatment arm. For the East
Asian group, there was no significant difference in OS be-
tween the pemetrexed and placebo treatment arms (although
OS was numerically greater in the pemetrexed group).
TABLE 2. Summary of Progression-Free Survival and Overall Survival for the East Asian and Non-East
Asian Subgroups
Survival Outcome
East Asian Non-East Asian
Pemetrexed
(n  88)
Placebo
(n  41)
Pemetrexed
(n  237)
Placebo
(n  115)
Investigator-assessed PFS
Median PFS time, mo (95% CI) 4.4 (4.1–6.4) 1.6 (1.4–2.9) 4.5 (4.2–5.6) 2.8 (1.7–2.9)
HR (95% CI), p 0.42 (0.28–0.65), p  0.001 0.45 (0.35–0.59), p  0.001
Patients with events, n (%) 70 (80) 36 (88) 162 (68) 96 (83)
Independently reviewed PFS
Median PFS time, mo (95% CI) 4.1 (2.9–5.7) 1.8 (1.5–3.0) 4.5 (4.0–5.9) 1.8 (1.5–2.8)
HR (95% CI), p 0.54 (0.35–0.83), p  0.005 0.45 (0.34–0.60), p  0.001
Patients with events, n (%) 68 (77) 29 (71) 164 (69) 67 (58)
Overall survival
Median OS time, mo (95% CI) 19.7 (16.4–22.7) 16.4 (12.1–26.4) 13.2 (11.3–15.9) 8.5 (7.2–10.8)
HR (95% CI), p 0.91 (0.57–1.43), p  0.670 0.63 (0.49–0.82), p  0.001
Patients with events, n (%) 59 (67) 27 (66) 154 (65) 92 (80)
Note for the nonsquamous patients in the entire study population, median PFS (95% CI) was 4.5 (4.2–5.6) months for pemetrexed and 2.6
(1.6–2.8) months for placebo; and median OS was 15.5 (13.2–18.1) months for pemetrexed and 10.3 (8.1–12.0) months for placebo.3
CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
FIGURE 2. Progression-free survival (PFS). Kaplan–Meier
curves for investigator-assessed PFS for the East Asian (top
panel) and the non-East Asian (bottom panel) groups. CI,
confidence interval; HR, hazard ratio.
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Safety
For the grade 3/4 drug-related treatment-emergent ad-
verse events, pemetrexed seemed to be better tolerated in the
East Asian group than in the non-East Asian group (Table 3).
Only 8% of patients in the East Asian group reported at least
one grade 3/4 drug-related adverse event compared with 17%
of patients in the non-East Asian group. For the East Asian
group, there were no significant differences in the frequency
of grade 3/4 drug-related treatment-emergent adverse events
between the pemetrexed and placebo treatment arms. For the
non-East Asian group, the frequency of grade 3/4 drug-
related treatment-emergent adverse events was significantly
greater in the pemetrexed group than the placebo group (17%
versus 5%, p  0.001), particularly for nonhematological
events (14% versus 3%, p 0.001). For example, fatigue was
experienced by 5% of patients in the pemetrexed group
compared with no patients in the placebo group (p  0.011).
Postdiscontinuation Therapy
More patients in the East Asian group received at least
one additional anticancer therapy after study treatment dis-
continuation than in the non-East Asian group (Table 4).
Approximately 80% of the East Asian patients received
anticancer therapy after study treatment discontinuation.
Most of the East Asian patients were treated with epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors
(gefitinib or erlotinib) or docetaxel. In contrast, few patients
from the non-East Asian group received gefitinib or docetaxel
after study treatment discontinuation.
DISCUSSION
The results of this exploratory subgroup analysis
showed that pemetrexed maintenance treatment for patients
with advanced, nonsquamous NSCLC is effective and well
tolerated in patients from East Asia (China, Korea, and
Taiwan). Although there were some differences in baseline
characteristics between patients from East Asia and patients
from non-East Asia, PFS in all patients who received pem-
etrexed maintenance and best supportive care was better than
PFS in patients on the placebo and best supportive care arm.
FIGURE 3. Overall survival (OS). Kaplan–Meier curves for
OS for the East Asian (top panel) and the non-East Asian
(bottom panel) groups. CI, confidence interval; HR, hazard
ratio.
TABLE 3. Percentages of Patients Who Had Clinically Important Grade 3/4 Drug-
Related Treatment-Emergent Adverse Events, n (%)
Treatment-Emergent Adverse Eventa
East Asian Non-East Asian
Pemetrexed
(n  87)
Placebo
(n  40)
Pemetrexed
(n  236)
Placebo
(n  113)
At least 1 event 7 (8) 1 (3) 41 (17) 6 (5)
At least 1 hematological event 4 (5) 0 16 (7) 3 (3)
-Glutamyl transpeptidase 0 0 0 1 (1)
Hemoglobin 0 0 8 (3) 0
Leukocytes (total white blood cells) 0 0 4 (2) 1 (1)
Neutrophils/granulocytes 2 (2) 0 7 (3) 0
Platelets 2 (2) 0 4 (2) 1 (1)
At least 1 nonhematological event 4 (5) 1 (3) 33 (14) 3 (3)
Anorexia 1 (1) 0 2 (1) 0
Cough 0 0 1 (1) 0
Diarrhea 0 0 1 (1) 0
Fatigue 0 1 (3) 12 (5) 0
Febrile neutropenia 0 0 3 (1) 0
Mucositis/stomatitis—oral cavity 0 0 2 (1) 0
Rash, acne/acneiform 0 0 1 (1) 0
a Adverse events were defined using Common Terminology for Criteria for Adverse Events v3.0.
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The efficacy of pemetrexed in East Asian patients in
this subgroup analysis was consistent with the results for the
entire study population.3 Median PFS for pemetrexed was 4.4
months (95% CI: 4.1–6.4 months) in the East Asian subgroup
and 4.5 months (95% CI: 4.2 – 5.6 months) in the non-East
Asian subgroup. This is also similar to the median PFS time
of 4.5 months (95% CI: 4.2–5.6) for pemetrexed for the
subgroup of patients with nonsquamous histology in the
entire study population. In summary, the results from this
subgroup analysis indicated that the East Asian patients
responded at least as well to maintenance pemetrexed therapy
as the entire multinational study population.
Of note, median OS times for both treatment arms were
numerically longer in the East Asian subgroup than in the
non-East Asian subgroup. The longer median OS times in the
East Asian subgroup may be due to a number of factors,
including greater use of postdiscontinuation anticancer ther-
apy, particularly gefitinib, genetic factors (such as a higher
rate of activating EGFR mutations),9–11 and a higher propor-
tion of patients with potentially favorable prognostic baseline
characteristics (never-smokers, women, and patients with
adenocarcinoma).3,12,13
The difference in median OS between the pemetrexed
and placebo arms was slightly smaller in the East Asian
subgroup (3.3 months) than in the non-East Asian subgroup
(4.7 months). OS was significantly longer for pemetrexed in
the non-East Asian group (HR 0.63, p 0.001) but did not
reach statistical significance in the East Asian group (HR 
0.91, p  0.670). This may have been be due to the same
factors described earlier that potentially explain the longer
median OS times in the East Asian subgroup as well as the
inherent better prognosis for the East Asian patients, which
would make it more difficult to show a significant difference
in OS between an active treatment and placebo in this
subgroup. In general, in a population with longer survival, the
same magnitude of improvement in the median OS time will
have a smaller impact on the HR than in a group of patients
with shorter initial survival.
Overall, the tolerability profile of pemetrexed was sim-
ilar to that observed for the entire JMEN study population.3
Pemetrexed was generally well tolerated by patients in both
the East Asian and the non-East Asian subgroups. A similar
proportion of patients in both the subgroups had at least one
hematological event, whereas a higher proportion of patients
in the non-East Asian subgroup had at least one nonhemato-
logical event. However, this could not be attributed to a
greater occurrence of any particular nonhematological event,
and the JMEN study was not sufficiently powered to deter-
mine whether there were significant differences in toxicity
between the subgroups of East Asian and non-East Asian
patients.
In conclusion, the results of this subgroup analysis
support the findings from the global study and suggest that
pemetrexed is an effective maintenance therapy option for the
East Asian patients with advanced, nonsquamous NSCLC.
However, interpretation of the findings from this subgroup
analysis should take into consideration the retrospective,
exploratory nature of the analyses and the relatively small
sample size, which limits the statistical power of the analyses.
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